Recent Updates
Recently added Catalysts
MIST Positive Sentiment

Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

Key Takeaway: Milestone Pharmaceuticals announced that key executives will present at the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, in Boston. The presentation will be available via webcast on March 3 at 9:10 AM EST, with a replay accessible for 90 days. The company focuses on innovative cardiovascular treatments, including its FDA-approved product, CARDAMYST™.
Price reaction · baseline $1.73 (2026-02-25 close) · hit pre-market · clean, no other MIST news in the window
day 0 close
-0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Milestone Pharmaceuticals is actively participating in a major healthcare conference.
  • The presentation will highlight innovative cardiovascular medicines.
  • The availability of a webcast allows broader access to the presentation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+75%
120-day peak, hindsight
Typical move
16.3%
average across 5 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
CX11
Phase 1 · Obesity & Overweight

Full Press Release Details

MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone®Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place March 2 - 4, 2026, in Boston.
A webcast of the presentation will be available on March 3rdat 9:10 AM EST. The webcast will be available to watchliveand there will be a replay for approximately 90-days following the presentation on the News & Events section of Milestone's website www.milestonepharma.com.
If you are interested in meeting with the Milestone team during the conference, please reach out to your TD Cowen representative.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the treatment of symptomatic episodic attacks associated with AFib-RVR.

Media RelationsRebecca Novak,rnovak@milestonepharma.com

Frequently Asked Questions

When will Milestone Pharmaceuticals present at the conference?

Milestone Pharmaceuticals will present at the TD Cowen Conference from March 2-4, 2026.

Who will represent Milestone Pharmaceuticals at the conference?

Amit Hasija, CFO, and Lorenz Muller, CCO, will represent Milestone Pharmaceuticals.

How can I access the presentation?

The presentation will be available via webcast on March 3 at 9:10 AM EST.

What is CARDAMYST™?

CARDAMYST™ is Milestone's FDA-approved nasal spray for treating PSVT.

Last updated: Feb 26, 2026